U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Ovarian Mucinous Adenocarcinoma

MedGen UID:
1791624
•Concept ID:
C5555183
•
Neoplastic Process

Definition

Ovarian mucinous adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Ovarian Mucinous Adenocarcinoma

Professional guidelines

PubMed

Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E
Oncology 2007;73(3-4):177-84. Epub 2008 Apr 16 doi: 10.1159/000127384. PMID: 18418010
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ
Ann Oncol 2001 Dec;12(12):1705-9. doi: 10.1023/a:1013558501425. PMID: 11843248

Recent clinical studies

Etiology

Rethinking the significance of surgery for uterine cervical cancer.
Shimada M, Tsuji K, Shigeta S, Nagai T, Watanabe Z, Tokunaga H, Kigawa J, Yaegashi N
J Obstet Gynaecol Res 2022 Mar;48(3):576-586. Epub 2021 Dec 14 doi: 10.1111/jog.15112. PMID: 34908207
HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.
Kim SK, Cho NH
Int J Clin Exp Pathol 2014;7(7):4222-30. Epub 2014 Jun 15 PMID: 25120802Free PMC Article
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y, Miyatake T, Nagamatsu M, Yamasaki M, Nishio Y, Yoshino K, Fujita M, Tsutsui T, Enomoto T, Kimura T
Eur J Obstet Gynecol Reprod Biol 2013 Sep;170(1):259-63. Epub 2013 Jul 20 doi: 10.1016/j.ejogrb.2013.06.035. PMID: 23880598
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S
Anticancer Res 2005 Sep-Oct;25(5):3501-5. PMID: 16101169

Diagnosis

Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.
Saran U, Arfuso F, Zeps N, Dharmarajan A
BMC Cell Biol 2012 Oct 8;13:25. doi: 10.1186/1471-2121-13-25. PMID: 23039795Free PMC Article
Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S
Anticancer Res 2005 Sep-Oct;25(5):3501-5. PMID: 16101169

Therapy

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM
Cancer 2016 Feb 15;122(4):588-597. Epub 2015 Nov 13 doi: 10.1002/cncr.29783. PMID: 26566079Free PMC Article
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y, Miyatake T, Nagamatsu M, Yamasaki M, Nishio Y, Yoshino K, Fujita M, Tsutsui T, Enomoto T, Kimura T
Eur J Obstet Gynecol Reprod Biol 2013 Sep;170(1):259-63. Epub 2013 Jul 20 doi: 10.1016/j.ejogrb.2013.06.035. PMID: 23880598
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S
Anticancer Res 2005 Sep-Oct;25(5):3501-5. PMID: 16101169
Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.
Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I
Int J Gynecol Cancer 2002 May-Jun;12(3):250-6. doi: 10.1046/j.1525-1438.2002.01096.x. PMID: 12060445

Prognosis

Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
Tarumi Y, Mori T, Matsushima H, Kokabu T, Tsuchiya H, Kitawaki J
J Obstet Gynaecol Res 2018 Feb;44(2):347-351. Epub 2017 Nov 9 doi: 10.1111/jog.13496. PMID: 29121427
HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.
Kim SK, Cho NH
Int J Clin Exp Pathol 2014;7(7):4222-30. Epub 2014 Jun 15 PMID: 25120802Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.
Saran U, Arfuso F, Zeps N, Dharmarajan A
BMC Cell Biol 2012 Oct 8;13:25. doi: 10.1186/1471-2121-13-25. PMID: 23039795Free PMC Article
Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S
Anticancer Res 2005 Sep-Oct;25(5):3501-5. PMID: 16101169

Clinical prediction guides

Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
Tarumi Y, Mori T, Matsushima H, Kokabu T, Tsuchiya H, Kitawaki J
J Obstet Gynaecol Res 2018 Feb;44(2):347-351. Epub 2017 Nov 9 doi: 10.1111/jog.13496. PMID: 29121427
HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.
Kim SK, Cho NH
Int J Clin Exp Pathol 2014;7(7):4222-30. Epub 2014 Jun 15 PMID: 25120802Free PMC Article
Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.
Saran U, Arfuso F, Zeps N, Dharmarajan A
BMC Cell Biol 2012 Oct 8;13:25. doi: 10.1186/1471-2121-13-25. PMID: 23039795Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...